Regulatory

The Annual General Meeting adopted the following resolutions:

• The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.

• The Board and the Chief Executive Officer were discharged from liability.

• The Board shall consist until the next AGM of five ordinary members without deputies.

• Re-election of Board members Torben Jørgensen, Mikael Lönn, Lotta Ljungqvist, Steve Jordan and Magnus Gustafsson Torben Jørgensen was elected Chairperson of the Board.

• Remuneration will be paid to the Board of Directors in the amount of SEK 240,000 to Board members and SEK 590,000 to the Chairperson of the Board.

• In accordance with the Nomination Committee’s proposal, the Meeting re-elected the accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the period until the close of the Annual General Meeting 2027.

• A nomination committee shall be formed consisting of the four largest shareholders as of the last banking day in August preceding the Annual General Meeting.

• The General Meeting approved the Board of Directors’ proposal regarding amendments to the guidelines for remuneration to senior executives, entailing that:

  • A provision has been added stating that the CEO’s variable remuneration will not be included in pension calculations.
  • The maximum level for other benefits has been aligned across the group of senior executives. Previously, the maximum value was 15 percent of the fixed annual salary for senior executives excluding the CEO, while the CEO was limited to 10 percent of the fixed annual salary. Under the current proposal, the limit is 10 percent of the fixed annual salary for all senior executives.
  • The percentage cap in the previous guidelines regarding any commitment to non-compete compensation upon termination of employment has been removed in order to compensate for the restriction resulting from such a commitment.

• The AGM resolved on the authorization to issue shares with or without preferential rights for existing shareholders. As a result of this resolution, share capital could increase by a maximum of SEK 1,650,000 through the issuance of a maximum of 6,600,000 shares.

• The General Meeting resolved to authorize the Board of Directors, on one or several occasions during the period up until the next Annual General Meeting, to resolve on acquisitions and transfers of the company’s own shares. Acquisitions may be made of such number of shares that the company’s holding does not exceed ten (10) percent of all shares in the company. The resolution is conditional upon the adoption of Government Bill 2025/26:125.

Minutes with all resolutions from the meeting will be made available on the company’s website:
https://investor.genovis.com/en/corporate-governance/general-meeting/

Regulatory

Genovis AB announces that Chief Financial Officer (CFO) Magnus Långberg has decided to leave the company to pursue a new opportunity outside the Group. Magnus Långberg will remain in his current role during a transition period to ensure a structured handover to his successor. Johan Dahlberg has been appointed as the new Chief Financial Officer and is expected to join in August 2026.

During his time at Genovis, Magnus Långberg has made valuable contributions to the company. He has played a significant role in professionalizing the finance function, strengthening Genovis’ operational foundation and contributing to the company’s positive development journey.

Johan Dahlberg will join Genovis as Chief Financial Officer (CFO) in August 2026. He comes most recently from Arcoma, a medtech company listed on Nasdaq First North, and has previously held senior financial roles at BIMobject and Qlik. In total, Johan brings approximately ten years of experience from growth companies, with a focus on financial control, capital markets presence and international expansion.

“I would like to extend my sincere thanks to Magnus for his contributions during his time at Genovis. By professionalizing the finance function, he has helped the company take important steps on our development journey. I wish him all the best going forward. I look forward with confidence to welcoming Johan Dahlberg — his experience and profile are a strong fit for Genovis at this stage of our journey, and I am convinced he will be a valuable addition to the team,” says Fredrik Olsson, CEO of Genovis.

“It has been a true privilege to be part of Genovis and to work alongside such a dedicated and skilled team. I am proud of the progress we have made together in professionalizing the company, and I look forward with great pleasure to following the company’s continued development and success,” says Magnus Långberg, CFO of Genovis.

Genovis AB and MGI Tech Co., Ltd. today announce a strengthened collaboration to advance RNA sequencing solutions. The companies have expanded their commercial agreement to integrate Genovis’ SEQURNA reagents with MGI Tech’s high-performance sequencing platforms, enabling researchers to benefit from enhanced RNA preservation and improved sequencing performance.

The partnership marks an important step for both organizations, bringing together Genovis’ SEQURNA technology with MGI’s RNA-seq library preparation kits. By combining complementary expertise, the collaboration aims to accelerate genomic research and enable more efficient, accurate, and scalable workflows across life science research and applied medtech markets.

“We are pleased to partner with Genovis to bring enhanced value to the genomics community,” said Duncan Yu, President at MGI. “Together, we are committed to supporting our customers with innovative technologies that deliver outstanding performance and dependable results.”

“Our partnership with MGI reflects our commitment to delivering innovative, high-performance genomics solutions,” said Fredrik Olsson, CEO at Genovis. “By combining our expertise, we deliver integrated technologies that enhance productivity, uphold the highest quality standards, and ensure cost efficiency.”

ABOUT MGI
MGI Tech Co., Ltd. (or its subsidiaries, together referred to as MGI) is committed to building core tools and technologies that drive innovation in life science. Our focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various other industries.
Founded in 2016, MGI has grown into a leader in life science, serving customers across six continents and establishing research, manufacturing, training, and after-sales service facilities globally. As one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers, MGI empowers global users with scalable sequencing capabilities ranging from Gb to Tb levels. MGI also stands out as one of the only providers of a full-stack product portfolio spanning three core segments: SEQ ALL (short- and long-read sequencing), GLI (Generative Lab Intelligence), and Multi-Omics. With unparalleled expertise, cutting-edge products, and a commitment to global impact, MGI continues to shape the trajectory of life sciences into the future.

MARRegulatory

Stable growth, new products, and expanded business opportunities

January – March 2026

• Net sales totaled SEK 33,506 (32,292) thousand, representing a growth of 4%, corresponding to 17% when adjusted for currency effects.
• Operating profit before depreciation and amortization (EBITDA) totaled SEK 9,510 (8,906) thousand.
• Earnings per share totaled SEK 0.06 (0.05).
• Cash flow from operating activities was SEK 16,511 (10,652) thousand.

Message from the CEO
The first quarter was marked by solid underlying growth, improved profitability, very strong cash flow, and high activity across several parts of our business.

Net revenue amounted to SEK 33,506 (32,292) thousand. Adjusted for currency effects, we grew 17 percent, and the reported growth of 4 percent reflects the significant headwind we face from the strengthening Swedish krona, which impacted sales by approximately SEK 4 million compared to the same quarter last year. The underlying business is sound and the direction is clear.

We saw strong development among large pharmaceutical companies during the quarter, with organic growth exceeding 30 percent in this segment. The biotech and academic markets remain below first quarter last year, but we note that the sequential recovery in the biotech segment that we observed in the fourth quarter of 2025 has continued into 2026 — which I view as a positive signal for the remainder of the year.

Service revenue was significantly lower in the quarter compared to the same period last year, largely explained by Q1 2025 containing larger project orders that have not been repeated in the early part of 2026. The nature of our service business means that individual larger project orders can create substantial variations between quarters. Product sales, excluding license revenues, developed strongly and showed currency-adjusted growth of approximately 27 percent.

Profitability improved during the quarter. EBITDA amounted to SEK 9,510 (8,906) thousand, corresponding to a margin of 28.4 percent (27.6) — an improvement that confirms our business model and cost discipline hold firm even in a challenging currency environment. Cash flow from operating activities improved strongly, reinforcing our financial position and flexibility.

Activity in the ADC space is increasing and we see growing interest in our technologies for the development of next-generation ADCs. During the quarter, we entered into a global, non-exclusive license agreement for our EndoS2 enzyme technology with a privately held biotechnology company focused on ADC therapies. The agreement generated initial license revenues and provides rights to milestone payments upon defined clinical and commercial progress — with up to approximately USD 20 million in total payments per program reaching commercialization. This is a strong validation of the strategic value of our enzyme technologies in one of the fastest-growing therapeutic areas.

During the quarter, we also launched LysCERATOR™, a new enzyme for protein analysis targeting proteomics and biopharmaceutical characterization. The launch was well received by the market and we saw rapidly growing customer interest among both large pharmaceutical companies and academic institutions across the US and Europe. Early customer feedback is positive, reinforcing our conviction that LysCERATOR addresses a genuine need in the market.

We also see markedly increased interest in our RNA analysis products. During the quarter, we entered into a strategic partnership with Single Cell Discoveries to broaden the application of SEQURNA RNase Inhibitor in advanced RNA sequencing workflows. We also launched SEQguard™ Dino Preserve in collaboration with Plasmidsaurus — a product that enables room-temperature transport of extracted RNA, eliminating the need for costly cold-chain logistics. The initial weeks following launch have shown excellent customer reception and a rapidly growing customer base, reinforcing our conviction that the SEQURNA platform has broad commercial potential.

We close the quarter with a strong financial position, improved profitability, and strong cash flow. While geopolitical and macroeconomic uncertainty continues to represent an external risk factor, I look with confidence to Genovis’ long-term growth opportunities. With a broadened and strengthened offering across both Genomics and ADC, increasing activity in the biotech segment, and a healthy core business, we are well positioned for continued progress in 2026.

Finally, I would like to thank all colleagues at Genovis for your commitment and contributions during the quarter. It is your work that creates value for our customers and lays the foundation for Genovis’ continued growth journey.

Regulatory

Genovis’ Annual Report 2025 is as of today available at **www.genovis.com **

Regulatory

The shareholders of Genovis AB (publ), reg.no. 556574-5345, with its registered office in Kävlinge kommun, Skåne län, are hereby summoned to the Annual General Meeting, to be held on Monday, 18 May 2026, at 17.00 p.m., at Genovis AB’s office, Karl Johans väg 104, Kävlinge.

4:30 p.m. – 4:50 p.m. Registration 5:00 pm Annual General Meeting convened

Right to Participate and Registration
Shareholders who wish to participate in the General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday, 7 May 2026, and must have notified the Company of their intention to attend no later than Tuesday, 12 May 2026, preferably before 15:00. Registration may be submitted by post to Genovis AB c/o Advokatfirman Källén AB, Stora Tomegatan 5, 223 51 Lund, or by e-mail: [email protected] When registering, please state your name/company name and personal identity number/corporate registration number, address and telephone number. The notification should also state the number of assistants (maximum two) the shareholder intends to bring to the meeting.

In order to be entitled to participate in the General Meeting, a shareholder whose shares are held in the name of a nominee must, in addition to notifying the Company of their intention to attend, have the shares registered in their own name so that the shareholder is included in the presentation of the share register as of the record date, Thursday, 7 May 2026. Such re-registration may be temporary (so-called voting rights registration) and must be requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting rights registrations completed by the nominee no later than Tuesday, 12 May 2026 will be taken into account in the preparation of the share register.

Proxies
A shareholder who is represented by a proxy must issue a written, signed and dated power of attorney to the proxy. Such power of attorney should be submitted in connection with the registration. The validity of a power of attorney may not exceed five years from the date of issue. A proxy form is available on the Company’s website, https://investor.genovis.com/en/corporate-governance/general-meeting/ . A representative of a legal entity must present a copy of the certificate of registration or equivalent authorization documents demonstrating the authorized signatory.

Proposed Agenda
1. Opening of the meeting.

2. Election of chairperson of the meeting.

3. Preparation and approval of the voting list.

4. Approval of the agenda.

5. Election of persons to verify the minutes.

6. Examination of whether the meeting has been duly convened.

7. Address by the Chief Executive Officer.

8. Presentation of the annual report and consolidated accounts and the auditor’s report.

9. Resolution on:

a) adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet,

b) allocation of the Company’s profit or loss in accordance with the adopted balance sheet,

c) discharge from liability for the members of the Board of Directors and the Chief Executive Officer.

10. Resolution on the number of members of the Board of Directors and deputy members to be elected by the General Meeting.

11. Resolution on fees to the members of the Board of Directors.

12. Election of members of the Board of Directors and the Chairman of the Board.

13. Resolution on fees to the auditors.

14. Election of auditor.

15. Resolution regarding the nomination committee.

16. Resolution on guidelines for remuneration of senior executives.

17. Resolution of authorization for the Board of Directors to resolve on new share issues.

18. Resolution on authorization for the Board of Directors to resolve on repurchase and transfer of own shares, conditional upon the adoption of legislative proposal prop. 2025/26:125.

19. Resolution on authorization for the Chief Executive Officer to make such formal adjustments to the resolutions as may be required in connection with their registration and implementation.

20. Closing of the meeting.

Item 2 – Proposed Chairperson of the Meeting
The nomination committee proposes attorney Arne Källén as chairperson of the meeting.

Item 10 – Number of Members of the Board of Directors and Deputy Members
The nomination committee proposes that the Board of Directors shall consist of five ordinary members without deputies.

Item 11 – Fees to the Members of the Board of Directors
The nomination committee proposes that fees until the end of the next Annual General Meeting shall be paid in the amount of SEK 240,000 to each member of the Board of Directors who is not employed by the Company, and SEK 590,000 to the Chairman of the Board.

Item 12 – Election of Members of the Board of Directors and Chairman of the Board
The nomination committee proposes the re-election of Torben Jørgensen, Mikael Lönn, Steve Jordan, Magnus Gustafsson and Lotta Ljungqvist as members of the Board.
The nomination committee proposes the re-election of Torben Jørgensen as Chairman of the Board.

Item 13 – Fees to the Auditors
The nomination committee proposes that fees to the auditors shall be paid in accordance with approved invoices.

Item 14 – Election of Auditor
The nomination committee proposes the re-election of the registered audit firm Öhrlings PricewaterhouseCoopers AB (“PWC”). PWC has announced that, if elected, PWC will appoint Neda Feher as the auditor in charge.

Item 15 – Resolution Regarding the Nomination Committee
The nomination committee proposes that the nomination committee for the Annual General Meeting 2027 shall consist of representatives of the four largest shareholders as of the last banking day in August prior to the Annual General Meeting. The nomination committee shall appoint a chairperson from among its members. It shall be the responsibility of the Chairman of the Board to convene the nomination committee. If any owner declines to participate in the nomination committee, the right to appoint a representative shall pass to the next largest shareholder not already represented on the nomination committee. If, as a result of changes in ownership, it is deemed appropriate, the nomination committee may invite additional shareholders to take a seat on the nomination committee, provided that the total number of members does not exceed five. If a member of the nomination committee were to leave the committee before its work is complete, the nomination committee shall, if it deems this necessary, request the same shareholder, or, if that shareholder is no longer among the larger shareholders, the next largest shareholder in terms of size, to appoint a replacement. Any such change shall be announced on the Company’s website. If only marginal changes in voting rights have occurred, or if the change occurs later than three months before the Annual General Meeting, no changes to the composition of the nomination committee shall be made, unless there are special reasons for doing so.

The nomination committee shall prepare proposals to be submitted to the Annual General Meeting for resolution regarding the chairperson of the meeting, the Chairman and other members of the Board of Directors, the auditor, fees to the Board of Directors and the auditor, and principles for the appointment of the nomination committee. The mandate of the nomination committee runs until a new nomination committee has been appointed.

The nomination committee proposes that remuneration shall only be paid for direct costs incurred in connection with the assignment.

Item 16 – Guidelines for Remuneration of Senior Executives
The Board of Directors proposes that the Annual General Meeting resolve on the following guidelines for remuneration of senior executives. Senior executives means the Chief Executive Officer and other members of group management. In the event that a member of the Board of Directors performs work for Genovis beyond board duties, consulting fees or other remuneration may be paid for such work. The guidelines shall apply to remuneration agreed upon, and changes made to previously agreed remuneration, after the guidelines have been adopted by the Annual General Meeting 2026. The guidelines do not cover remuneration resolved by the General Meeting.

Promotion of the Company’s Business Strategy, Long-Term Interests and Sustainability
In brief, the Company’s business strategy is to develop innovative and effective solutions for the research, development and manufacture of pharmaceuticals. The strategy for conducting successful operations and achieving the Company’s financial goals consists of developing new innovative products, building long-term customer relationships and inorganic growth initiatives within the focus areas: biochemical analysis, diagnostics and applications in the manufacture of biological pharmaceuticals. Further information about the Company’s business strategy is available at www.genovis.com.
Successful implementation of the Company’s business strategy and safeguarding of the Company’s long-term interests, including its sustainability, requires the Company to be able to recruit and retain qualified employees. This requires the Company to be able to offer competitive remuneration. These guidelines enable senior executives to be offered competitive total remuneration.
Variable cash remuneration covered by these guidelines shall aim to promote the Company’s business strategy and long-term interests, including its sustainability.

Forms of Remuneration, etc.
Remuneration shall be market-based and may consist of the following components: fixed annual salary, variable cash remuneration, pension benefits, other benefits and severance pay. In addition, and independently of these guidelines, the General Meeting may resolve on, for example, share and share price-related remuneration.

Fulfilment of criteria for the payment of variable cash remuneration shall be measurable over a period of one year and may amount to at most a certain percentage, see below, of the fixed cash annual salary.

Chief Executive Officer
The Company’s Chief Executive Officer shall receive fixed and variable cash remuneration. Pension benefits, including health insurance, shall be defined contribution. Variable cash remuneration shall not qualify for pension. The Company shall make pension provisions of a maximum of 35 percent of the fixed cash annual salary. In addition to the fixed cash annual salary, the Chief Executive Officer shall receive variable cash remuneration that may amount to a maximum of 50 percent of the fixed cash annual salary per year. The variable portion of the cash remuneration is based on the Company achieving certain predetermined and measurable criteria, which may be financial or non-financial, and may also consist of individually adapted quantitative or qualitative targets. The criteria shall be designed to promote the Company’s business strategy and long-term interests, including its sustainability, by for example having a clear link to the business strategy or promoting the Chief Executive Officer’s long-term development.

Other Senior Executives
This group shall receive a market-based fixed cash annual salary as well as variable cash remuneration that may amount to a maximum of 50 percent of the fixed annual salary per year. The variable cash remuneration shall be based on the Company achieving certain predetermined and measurable criteria, which may be financial or non-financial (such as ESG). The variable cash remuneration shall also, to a certain extent, be based on predetermined targets related to individual performance and shall consist of predetermined and measurable quantitative or qualitative targets. The criteria shall be designed to promote the Company’s business strategy and long-term interests, including its sustainability, by for example having a clear link to the business strategy or promoting the executive’s long-term development.

Pension benefits, including health insurance, shall be defined contribution unless the executive is covered by defined benefit pension under mandatory collective bargaining agreement provisions. Variable cash remuneration shall qualify for pension to the extent required by mandatory collective bargaining agreement provisions applicable to the executive. Pension premiums for defined contribution pension may amount to a maximum of 35 percent of the fixed annual salary.

Conditions for Variable Remuneration and Performance Requirements
Variable cash remuneration is linked to certain predetermined and measurable criteria as described above. When the measurement period for fulfilment of criteria for payment of variable cash remuneration has ended, an assessment shall be made of the extent to which the criteria have been met. The Board of Directors is responsible for the assessment regarding variable cash remuneration for the Chief Executive Officer. Regarding variable cash remuneration for other executives, the Chief Executive Officer is responsible for the assessment. Regarding financial targets, the assessment shall be based on the most recently published financial information of the Company.

Cash Remuneration in Extraordinary Circumstances
In addition to the above, additional variable cash remuneration may be paid in extraordinary circumstances, provided that such extraordinary arrangements are time-limited and only made at the individual level, either for the purpose of recruiting or retaining executives, or as remuneration for extraordinary work efforts beyond the person’s ordinary duties. Such remuneration may not exceed an amount corresponding to 35 percent of the fixed cash annual salary per year and may not be paid more than once per year and per individual. Any decisions on such remuneration shall be made by the Board of Directors.

Derogation from the Guidelines
The Board of Directors may resolve to temporarily derogate from these guidelines, in whole or in part, if the Board of Directors in an individual case assesses that there are special reasons warranting such derogation and it is necessary to serve the Company’s long-term interests, including its sustainability, or to ensure the Company’s financial viability.

Other Benefits
Senior executives may be granted customary benefits, which may include, inter alia, a company car, occupational health services and life insurance. Such benefits may amount to a maximum value corresponding to ten percent of the fixed cash annual salary.

Severance Pay
Upon termination by the Company, the notice period may be a maximum of 12 months. Fixed cash salary during the notice period and severance pay may together not exceed an amount corresponding to 18 months’ fixed cash salary for the Chief Executive Officer and 12 months for other senior executives. Upon termination by the executive, the notice period may be a maximum of six months, without entitlement to severance pay.

In addition, remuneration for any non-compete undertaking may be paid. Such remuneration shall compensate for any loss of income and shall only be paid to the extent that the former executive does not have entitlement to severance pay. The remuneration shall be based on the fixed cash salary at the time of termination, unless otherwise required by mandatory collective bargaining agreement provisions, and shall be paid during the period in which the non-compete undertaking applies, which shall be a maximum of nine months after the end of employment.

Salary and Employment Conditions for Employees
In preparing the Board of Directors’ proposal for these guidelines, salary and employment conditions for the Company’s employees have been taken into account, with data on employees’ total remuneration, the components of remuneration and the increase and rate of increase in remuneration over time having formed part of the Board of Directors’ basis for decision in evaluating the reasonableness of the guidelines and the limitations that follow therefrom.

The Decision-Making Process for Determining, Reviewing and Implementing the Guidelines
The Board of Directors prepares proposals for guidelines for remuneration of senior executives. The Board of Directors shall prepare a proposal for new guidelines at least every four years and submit the proposal for resolution at the Annual General Meeting. The guidelines shall apply until new guidelines have been adopted by the General Meeting. The Board of Directors shall monitor and evaluate programs for variable remuneration for company management, the application of guidelines for remuneration of senior executives and current remuneration structures and levels in the Company. When the Board of Directors processes and resolves on remuneration-related matters, the Chief Executive Officer and other members of company management do not participate, to the extent they are affected by the matters.

Description of Material Changes to the Guidelines and How Shareholders’ Views Have Been Taken into Account
Compared to the previously adopted guidelines, the following changes have been made to these proposed guidelines:
• An addition that the Chief Executive Officer’s variable remuneration shall not qualify for pension.
• The maximum scope for other benefits has been made uniform across the group of senior executives. Previously, the maximum value was 15 percent of the cash annual salary for senior executives excluding the Chief Executive Officer, who had a limit of ten percent of the cash annual salary. The current proposal is a limit of ten percent of the cash annual salary for all senior executives.
• The percentage cap in the previous guidelines regarding any non-compete undertaking upon termination of employment has been removed, in order to compensate for the limitation following from such an undertaking.
Beyond what is mentioned above, no material changes have been made to these proposed guidelines compared to the previously adopted guidelines.

Item 17 – Board of Directors’ Proposal for Authorization to Resolve on New Share Issues
The Board of Directors proposes that the General Meeting authorize the Board of Directors to resolve, on one or more occasions during the period up to and including the next Annual General Meeting, with or without preferential rights for shareholders, to issue new shares, convertibles or warrants. New issues may be made against cash payment and/or with provisions for payment in kind, set-off or other conditions. Through resolutions made pursuant to the authorization, the share capital may be increased by a total maximum of SEK 1,650,000 through the issuance of a total maximum of 6,600,000 new shares. In the event of issues without preferential rights for shareholders, the subscription price shall be market-based at the time of the issue resolution.

The reason for any deviation from shareholders’ preferential rights shall be to broaden the shareholder base, raise or facilitate the raising of working capital, increase liquidity in the share, carry out company acquisitions or raise or facilitate the raising of capital for company acquisitions.

A valid resolution under this item requires that the resolution be supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the General Meeting.

Item 18 – Authorization for the Board of Directors to Resolve on Repurchase and Transfer of Own Shares, Conditional upon the Adoption of Legislative Proposal prop. 2025/26:125
The Swedish Government has, in legislative bill 2025/26:125, proposed an amendment to the Swedish Companies Act (Sw. aktiebolagslagen) such that the possibility for public limited liability companies to acquire and transfer own shares shall also apply to companies whose shares are admitted to trading on an MTF platform, including Nasdaq First North Growth Market. The legislative amendments are proposed to enter into force on 5 December 2026. The Board of Directors’ right to utilize the authorization is conditional upon the Swedish Companies Act being amended such that acquisition and transfer of own shares shall also be permitted for companies whose shares are admitted to trading on an MTF platform.
The Board of Directors proposes that the Annual General Meeting authorize the Board of Directors to resolve, on one or more occasions during the period up to and including the next Annual General Meeting, to acquire and transfer own shares on the following terms.
Repurchases of shares may be made on Nasdaq First North Growth Market in accordance with the Nasdaq First North Growth Market Rulebook for Issuers of Shares. The maximum number of own shares that may be repurchased shall not exceed ten (10) percent of all shares in the Company at any given time. Repurchases of shares may only be made at a price per share within the prevailing price range for the share on Nasdaq First North Growth Market at the time of the repurchase. Repurchases shall be made against cash payment.
Transfers may be made of all own shares held by the Company at the time of the Board of Directors’ transfer resolution. Transfers of own shares on Nasdaq First North Growth Market may only be made at a price per share within the prevailing price range for the share on Nasdaq First North Growth Market at the time of the transfer. Transfers of own shares in a manner other than on Nasdaq First North Growth Market shall be made against cash payment, through contribution of assets in kind or through set-off, and the price shall be determined such that the transfer is made on market-based terms. Transfers of own shares in a manner other than on Nasdaq First North Growth Market may be made with deviation from shareholders’ preferential rights.
The purpose of an acquisition or transfer of own shares, and the reason for any transfer with deviation from shareholders’ preferential rights, shall be to enable adjustment and improvement of the Company’s capital structure in order to contribute to increased shareholder value, and to capitalize on strategic business opportunities by financing such opportunities in whole or in part with own shares.
The Board of Directors’ proposal for a resolution to authorize the Board of Directors to resolve on repurchase and transfer of own shares is conditional upon the Swedish Companies Act being amended such that acquisition and transfer of own shares shall also be permitted for companies whose shares are admitted to trading on an MTF platform. The resolution shall not be valid and shall not be implemented in the event that the Swedish Parliament does not adopt such legislative amendments, or until such legislative amendments have entered into force.

Documents
The annual report, auditor’s report, articles of association, proxy form and the other proposed resolutions will be available at the Company’s offices at Karl Johans väg 104, Kävlinge and on the Company’s website www.genovis.com no later than three weeks prior to the Annual General Meeting and will be sent to shareholders who so request and provide their postal address. The Nomination Committee’s reasoned statement will be available at the above mentioned address no later than four weeks prior to the Annual General Meeting.

Number of Shares and Votes
At the time of issuance of this notice, the total number of shares and votes in the Company amounts to 66,062,792.

Information at the Annual General Meeting
Shareholders are reminded of their right to request information from the Board of Directors and the Chief Executive Officer at the General Meeting pursuant to Chapter 7, Sections 32 and 57 of the Swedish Companies Act. Shareholders that wish to submit written requests for such information in advance of the Annual General Meeting may do so to Genovis AB, Att: Legal, Box 4, 244 21 Kävlinge, or by e-mail to: [email protected].

Kävlinge, April 2026
Genovis AB (publ)
The Board of Directors

Genovis AB today announces the commercial launch of SEQguard™ Dino Preserve, an RNA preservation product tested and optimized for Plasmidsaurus, a leading Sequencing as a Service company. The product enables researchers to ship extracted RNA samples at ambient temperatures, eliminating the need for dry ice or cold-chain logistics and making high-quality RNA sequencing more accessible, cost-efficient, and sustainable.

Maintaining RNA integrity during transport has historically required cold-chain logistics involving dry ice or liquid nitrogen — adding cost, logistical complexity, and environmental burden to RNA sequencing workflows. SEQguard™ Dino Preserve addresses this challenge directly, allowing researchers to ship extracted RNA at ambient temperatures without compromising sequencing yield and quality. The product has been validated for seamless integration with Plasmidsaurus’ high-throughput sequencing infrastructure and ultrafast-turnaround service.

The solution delivers a compelling combination of customer benefits: researchers can ship RNA samples reliably at ambient temperatures, significantly reducing shipping costs compared to dry ice logistics while substantially lowering the carbon footprint associated with cold-chain transport. By removing dependency on frozen shipping, SEQguard™ Dino Preserve simplifies sample preparation and gives researchers peace of mind that their samples will arrive intact and sequencing-ready, even over extended shipping times and across distances and climates.

Developed through close collaboration between Genovis’ and Plasmidsaurus’ teams, this innovation is specifically tailored for Plasmidsaurus customers and optimized to integrate seamlessly with their sequencing workflows. It enables consistent, high-quality gene expression profiling from RNA samples shipped globally at ambient temperature. The product is available immediately to Plasmidsaurus’ customers working in RNA sequencing.

“By partnering with Genovis to bring SEQguard™ Dino Preserve into the Plasmidsaurus ecosystem, we’re making high-quality RNA-seq as simple and reliable as dropping off a tube at a local drop box. Together, we eliminate the logistical headache so customers can focus on their science, not shipping — unlocking unprecedented simplicity for ultrafast, high-quality gene expression data,” said Mark Budde, CEO and co-founder of Plasmidsaurus.

“The launch of SEQguard™ Dino Preserve is a strong example of how we are expanding the commercial application of our SEQURNA technology platform,” said Fredrik Olsson, CEO at Genovis. “Powered by the SEQURNA team’s expertise and innovation, this purpose-built solution tackles a persistent challenge in sequencing logistics — delivering speed, cost savings and a meaningfully smaller carbon footprint. This demonstrates both the breadth of our technology platform and our ability to create tangible value for researchers.”

RNA sequencing is among the fastest-growing areas of molecular biology and drug development, driven by advances in transcriptomics, multiomics, single-cell analysis, and target discovery. As throughput increases and sequencing costs decline, sample logistics and workflow efficiency are increasingly important factors in making RNA-seq services globally accessible.

More about SEQguard™ Dino Preserve

ABOUT PLASMIDSAURUS
Plasmidsaurus is on a mission to accelerate science with the best sequencing. The company’s sequencing services, spanning whole plasmids, RNA-seq, amplicons, whole genomes, and microbiomes, are used daily by thousands of innovators, including Nobel Prize winners, dynamic biotech startups, pharmaceutical companies, research labs, and DIY biohackers. Plasmidsaurus’s global network of labs operates day and night to enable world-changing discoveries. For more, visit: plasmidsaurus.com

• Company Overview

  • Goals

  • Strategy

  • Policys

  • Brief History

  • Five Year Summary

• Corporate Governance

  • General Meeting

  • Election of Board of Directors / Nomination Committee

  • Board of Directors

  • Senior Executives

  • Auditors

  • Articles of Association

• Press Releases

  • Subscribe

• Reports

  • Interim Reports

  • Annual Reports

  • Subscribe

• The Share

  • History of the Share

  • Ownership

  • Analyst

  • Subscribe

• IR Contact

March 25, 2026

Genovis Enters Non-Exclusive License Agreement for EndoS2 Enzyme Technology for Antibody-Drug Conjugate (ADC) Development and Commercialization

MARRegulatory

Genovis AB announces that it has entered into a non-exclusive, worldwide license agreement with a US-based private biotech company, granting rights to use Genovis’ proprietary EndoS2 enzyme technology for the research, development, manufacture, and commercialization of antibody-drug conjugate (ADC) therapeutics.

Under the terms of the agreement, the licensee — a private biotech company incorporated in the United States with a development pipeline focused on ADC therapeutics — receives a non-exclusive worldwide license under Genovis’ patent portfolio covering the EndoS2 enzyme and its related methods of use. The license enables the licensee to research, develop, manufacture, and commercialize ADC products across all therapeutic indications and covers multiple ADC programs.

The agreement entitles Genovis to an upfront access fee and milestone payments. Reflecting the licensee’s multi-program ADC development model, the agreement uses milestone-based payments triggered at defined development and commercial thresholds rather than running royalties. Designed to encompass multiple ADC programs, the agreement enables each program that successfully reaches commercialization to generate up to approximately USD 20 million in total payments to Genovis.

“This agreement is a strong validation of the utility of our EndoS2 enzyme technology in the rapidly expanding ADC field. Site-specific conjugation technologies are increasingly recognized as a key differentiator in next-generation ADC development, and we are proud to support a dedicated ADC-focused company as they advance their pipeline,” said Fredrik Olsson, CEO at Genovis.

EndoS2 is an IgG-specific endoglycosidase that selectively cleaves N-linked glycans from the Fc region of IgG antibodies, enabling precise, site-specific conjugation of payloads to create homogeneous ADCs with well-defined DAR (Drug-to-Antibody Ratios) — a critical quality attribute influencing both the safety and efficacy of ADC therapeutics. ADCs are one of the fastest-growing drug classes in oncology, with a robust global pipeline of clinical-stage programs and multiple products already approved.

• Company Overview

  • Goals

  • Strategy

  • Policys

  • Brief History

  • Five Year Summary

• Corporate Governance

  • General Meeting

  • Election of Board of Directors / Nomination Committee

  • Board of Directors

  • Senior Executives

  • Auditors

  • Articles of Association

• Press Releases

  • Subscribe

• Reports

  • Interim Reports

  • Annual Reports

  • Subscribe

• The Share

  • History of the Share

  • Ownership

  • Analyst

  • Subscribe

• IR Contact

March 19, 2026

Genovis and Single Cell Discoveries Enter Strategic Partnership for Large-Scale Transcriptomics Analyses

Genovis AB, a leading provider of innovative enzyme technologies, today announces a strategic partnership with Single Cell Discoveries to broaden the application of the SEQURNA® Thermostable RNase Inhibitor across advanced single-cell and bulk RNA-sequencing workflows.

The collaboration brings together Genovis’ expertise in developing high-performance molecular tools and Single Cell Discoveries’ extensive experience in RNA sequencing and transcriptomics. Through this partnership, the two companies will enable fast, sensitive RNA-sequencing readouts for the scientific community, supporting more complete Mechanisms of Action assays and higher-throughput target discovery for drug development.

The SEQURNA® Thermostable RNase Inhibitor is designed to streamline RNA-sequencing workflows while improving library quality and minimizing batch variation. Its thermostable properties ensure robust protection of RNA integrity across demanding molecular biology applications.

“The partnership with Genovis strengthens Single Cell Discoveries’ commitment to offer the best transcriptomics tools to researchers and drug development teams worldwide. We look forward to continuing to bring superior sensitivity and scalability to our discovery services,” said Mauro Muraro, CEO at Single Cell Discoveries.

“We are proud to enter this strategic collaboration with Single Cell Discoveries. Together, we are strengthening innovation, performance, and reliability in transcriptomics workflows to better support research and drug development,” said Fredrik Olsson, CEO at Genovis.

The partnership reflects both companies’ shared commitment to advancing transcriptomics technologies and delivering high-quality, validated reagents and services that meet the evolving needs of the life science community.

ABOUT SINGLE CELL DISCOVERIES
Single Cell Discoveries (Utrecht, The Netherlands) is a Contract Research Organization (CRO) dedicated to single-cell sequencing, bulk and spatial transcriptomics. The company provides high-impact insights to biopharmaceutical companies and academic research centers globally. Founded in 2018 as a spin-off from the Hubrecht Institute, Single Cell Discoveries offers end-to-end services from experimental design to sequencing and data analysis, and is the world’s only CRO specialized in single-cell sequencing for preclinical discovery work.

For additional information, please contact:
Fredrik Olsson, CEO, Genovis AB
T: +46 (0)70 276 46 56
E: [email protected]

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

• Company Overview

  • Goals

  • Strategy

  • Policys

  • Brief History

  • Five Year Summary

• Corporate Governance

  • General Meeting

  • Election of Board of Directors / Nomination Committee

  • Board of Directors

  • Senior Executives

  • Auditors

  • Articles of Association

• Press Releases

  • Subscribe

• Reports

  • Interim Reports

  • Annual Reports

  • Subscribe

• The Share

  • History of the Share

  • Ownership

  • Analyst

  • Subscribe

• IR Contact

February 12, 2026

Genovis AB Year-end Report January-December 2025

MARRegulatory

Strong finish to the year – recovery in customer activity in the fourth quarter

October – December 2025

• Net sales totaled SEK 40,252 (27,936) thousand, representing a growth of 44%, corresponding to 58% when adjusted for currency effects. The quarter’s sales include the entire order from a global pharmaceutical company, as previously communicated, amounting to SEK 10.9 million.
• Operating profit before depreciation and amortization (EBITDA) totaled SEK 11,737 (7,771) thousand.
• As a result of the Swedish krona strengthening against both the USD and the EUR, with the largest appreciation and impact related to the USD, EBITDA was negatively affected by foreign exchange translation effects amounting to SEK -1,027 (1,644) thousand.
• Earnings per share totaled SEK 0.10 (0.07).
• Cash flow from operating activities was SEK 15,895 (18,598) thousand.

 January – December 2025

• Genovis AB acquired the remaining 75% of Sequrna AB on July 1, 2025, by exercising the purchase option that had been agreed upon in connection with the acquisition of 25% of Sequrna AB in July 2024.
• Net sales totaled SEK 128,946 (109,970)1 thousand, representing growth of 17% excluding items affecting comparability2, corresponding to 23% when adjusted for currency effects.
• Operating profit before depreciation and amortization (EBITDA) totaled SEK 33,558 (30,688)1 thousand excluding items affecting comparability2.
• As a result of the Swedish krona strengthening during the period against both the USD and the EUR, with the greatest strengthening and impact related to the USD, the operating profit was impacted by currency translation effects amounting to -5,116 (1,360) thousand SEK.
• Earnings per share totaled SEK 0.36 (0.50).
• Cash flow from operating activities was SEK 32,022 (37,116) thousand. SEK -6,873 thousand refers to the payment of tax on the profit from the divestment of the antibody business in 2024.

1__Previous year excluding the divested antibody business and excluding non-recurring license revenues. The antibody business was divested on August 19, 2024.
2__Items affecting comparability for the full year relate to the divested antibody business and non-recurring license revenues in the previous year. In the previous year, including items affecting comparability, net sales amounted to SEK 130,358 thousand and EBITDA amounted to SEK 56,178 thousand, of which the gain from the divestment of the antibody business contributed SEK 14,925 thousand.

Message from the CEO
The fourth quarter marked a strong end to the year for Genovis, with a recovery in customer activity and very strong sales growth. Net sales amounted to SEK 40,252 (27,936) thousand, corresponding to growth of 44 percent compared with the same period last year, or 58 percent adjusted for currency effects.

For the full year, we also delivered strong sales development in our core business, with sales increasing by 17 percent, corresponding to 23 percent adjusted for currency effects. As the previous year included non-recurring license income as well as revenue from the divested antibody business, this year’s performance reflects solid organic growth in the underlying business and strengthened momentum in our long-term growth journey.

Growth during the quarter was partly driven by a larger order within antibody conjugation, while we also demonstrated stable growth in the underlying business adjusted for currency effects. We saw organic growth across key customer segments, including both biotech companies and larger pharmaceutical companies. Compared to the lower customer activity in the biotech segment in the third quarter, we noted strong sales growth in the final quarter of the year. We view this as an indication that demand in the segment is once again improving, particularly in the US market.

The strengthened Swedish krona continues to represent a currency headwind and had a negative impact on earnings of approximately SEK 2.6 million compared with the previous year. Despite this currency headwind, we continue to demonstrate strong profitability, healthy gross margins, and solid cash generation. EBITDA margin amounted to 29 percent during the quarter, underlining the strength of our business model and our cost discipline even in a period of negative currency effects. Cash flow from operating activities amounted to SEK 15,895 thousand, further strengthening our financial position and providing continued capacity to invest in future growth.
 
During the quarter, we also carried out an important antibody conjugation project, successfully meeting the customer’s high expectations by delivering the full order within the same quarter. The customer has confirmed that all quality parameters were fulfilled and that the material can be used in the continued development of a new drug candidate. Under significant time pressure, our team completed the project, which required substantial resources across several parts of the organization during the fourth quarter. I would like to extend my sincere thanks to all colleagues who, with great dedication and professionalism, contributed to a successful delivery.
 
We also saw an increase in personnel expenses compared with the corresponding quarter of the previous year. This is partly driven by a higher number of employees at Genovis, as well as Sequrna being fully integrated into the Group for the entire quarter.
 
In summary, we end the year with strong sales growth, stable development in the underlying business, and continued strong cash flow. With a strengthened position in both antibody conjugation and Genomics, as well as increasing customer activity in our most important markets, we are well positioned for continued growth. Although geopolitical and macroeconomic volatility remain short-term uncertainty factors, I remain confident in our long-term growth opportunities.
 
Finally, I would like to thank all colleagues at Genovis for their strong commitment and contributions during the quarter. Through your efforts, we continue to support the developers of tomorrow’s medicines with innovative technologies that enable new scientific breakthroughs.

• Company Overview

  • Goals

  • Strategy

  • Policys

  • Brief History

  • Five Year Summary

• Corporate Governance

  • General Meeting

  • Election of Board of Directors / Nomination Committee

  • Board of Directors

  • Senior Executives

  • Auditors

  • Articles of Association

• Press Releases

  • Subscribe

• Reports

  • Interim Reports

  • Annual Reports

  • Subscribe

• The Share

  • History of the Share

  • Ownership

  • Analyst

  • Subscribe

• IR Contact

November 7, 2025

Genovis AB Interim report January-September 2025

MARRegulatory

Shift in Growth Timing in a Volatile Market – Strong Start to the Fourth Quarter

July – September 2025

• Genovis AB acquired the remaining 75% of Sequrna AB on July 1, 2025, by exercising the purchase option that had been agreed upon in connection with the acquisition of 25% of Sequrna AB in July 2024.
• Net sales totaled SEK 27,532 (31,625)1 thousand, representing a decrease of 13% excluding items affecting comparability2, corresponding to -7% when adjusted for currency effects. Sales for the corresponding period last year included a large service order of approximately SEK 4 million within our ADC technology. This type of business is more volatile between quarters compared to the regular product business.
• Operating profit before depreciation and amortization (EBITDA) totaled SEK 6,878 (10,828)* thousand excluding items affecting comparability2.
• Earnings per share totaled SEK 0.12 (0.21).
• Cash flow from operating activities was SEK 10,875 (723) thousand.

 January – September 2025

• Net sales totaled SEK 88,694 (82,034)1 thousand, representing growth of 8% excluding items affecting comparability3, corresponding to 12% when adjusted for currency effects.
• Operating profit before depreciation and amortization (EBITDA) totaled SEK 21,820 (22,917)1 thousand excluding items affecting comparability3.
• As a result of the Swedish krona strengthening during the period against both the USD and the EUR, with the greatest strengthening and impact related to the USD, the operating profit was impacted by currency translation effects amounting to -4,068 (-284) thousand SEK.
• Earnings per share totaled SEK 0.25 (0.43).
• Cash flow from operating activities was SEK 16,126 (18,518) thousand. SEK -6,873 thousand refers to the payment of tax on the profit from the divestment of the antibody business in 2024.

1__Previous year excluding the divested antibody business and excluding non-recurring license revenues. The antibody business was divested on August 19, 2024.
2__Items affecting comparability in the third quarter relate to the divested antibody business in the previous year. In the previous year, including items affecting comparability, net sales amounted to SEK 32,895 thousand and EBITDA amounted to SEK 24,566 thousand, of which the gain from the divestment of the antibody business contributed SEK 14,925 thousand.
3__Items affecting comparability for the first nine months relate to the divested antibody business and non-recurring license revenues in the previous year. In the previous year, including items affecting comparability, net sales amounted to SEK 102,422 thousand and EBITDA amounted to SEK 48,407 thousand, of which the gain from the divestment of the antibody business contributed SEK 14,925 thousand.
 
Message from the CEO
The third quarter showed lower revenue compared to the same period last year, but the decline is primarily attributable to timing effects from larger individual customer orders. In the third quarter of 2024, revenue included a project order of nearly SEK 4 million, whereas a significantly larger order of SEK 11 million was received shortly after the end of this quarter. Such quarterly variations are natural in our business and do not alter the underlying positive growth trend.
 
In addition to timing effects, a more cautious sentiment in the biotech segment, particularly in the United States, affected sales. Uncertainty surrounding FDA priorities and NIH funding levels has led several venture-backed companies to reduce their investments. In my assessment, the weakest period is now behind us. The start of the fourth quarter shows clear signs of recovery within biotech, with customer activity increasing again, especially in the U.S. market.
 
At the same time, our business with large pharmaceutical and biopharma companies continues to grow steadily, helping to broaden and strengthen our customer base. In the third quarter, organic sales in this customer segment increased by approximately 30 percent, and for the first nine months of the year the increase amounts to 19 percent, adjusted for currency effects. The strengthening of the Swedish krona against the U.S. dollar has had a negative impact on our U.S. revenues of around SEK 2 million compared with the same quarter last year.
 
Despite temporarily lower sales, we maintained solid profitability. The EBITDA margin amounted to 25 percent, including non-recurring costs of SEK 1.3 million related to the acquisition of Sequrna. Adjusted for these costs, the margin was approximately 30 percent, confirming strong cost control and operational efficiency even in a quarter with lower revenue.
 
At the same time, we continue to invest actively in future growth. The acquisition of Sequrna strengthens our position within Genomics, where sales of Sequrna’s RNAse inhibitor continue to develop well compared with the previous year. We recently expanded a supply agreement with a leading international manufacturer of research kits, meaning that Sequrna’s product is now integrated into the partner’s kits for global distribution – an important step in our strategy to increase accessibility to our technologies.
 
Through the licensing agreement with Thermo Fisher Scientific within conjugation technology, we are also broadening our offering to cover the entire chain from preclinical development to commercial manufacturing. This opens new volume opportunities in the bioprocess area as our customers move towards commercialization of their conjugated drugs. Shortly after the end of the quarter, we received an order worth approximately SEK 11 million from a global pharmaceutical company. The order covers materials and services related to one of our conjugation technology platforms and will be used in the development of a new drug candidate. The agreement represents an important milestone in the development of our conjugation technologies and confirms their growing relevance for the medicines of the future.
 
Overall, I view the third quarter as a result of normal variations in our sales between quarters rather than a change in the underlying growth trend. With a strong start to the fourth quarter, increased customer activity, and a substantial order from a global biopharma company, I remain confident in the outlook for the remainder of the year and in our long-term growth potential.
 
Finally, I would like to thank all my colleagues at Genovis for their strong commitment and efforts during the quarter. Through your work, we continue to support the developers of tomorrow’s medicines with innovative technologies that enable new scientific breakthroughs.